Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Hisamitsu Pharmaceutical Co., Inc.
483
•Hisamitsu Pharmaceutical Co., Inc.•July 11, 2025

Hisamitsu Pharmaceutical Co., Inc. – FDA 483, Jul 11, 2025

Record Details

An FDA Form 483 was issued to the manufacturing facility managed by Norifumi Tanida following an inspection conducted from July 7-11, 2025. The observations highlight significant deficiencies in the firm's quality control and manufacturing processes for drug products. Key violations include a pervasive failure to thoroughly investigate unexplained discrepancies and batch failures. This was evident in inadequate investigations for a foreign matter incident involving metal fragments and multiple customer complaints concerning product defects and adverse events. The firm also failed to establish scientifically sound specifications and test procedures, specifically lacking impurity testing and specifications for drug products with active ingredients known to contain impurities. Furthermore, the stability program was deemed inadequate, as stability testing methods did not include known or unknown impurities, and there was no data demonstrating that assay testing methods were stability-indicating. Additional issues included incomplete laboratory records, with the use of unqualified secondary reference standards, and cleaning validation studies that failed to assess microbial contamination risk for equipment. These observations indicate non-compliance with Current Good Manufacturing Practices (CGMP) for drug products. The facility is required to respond to these findings by developing and implementing comprehensive corrective and preventive actions to ensure product quality, safety, and regulatory adherence.

Company
Hisamitsu Pharmaceutical Co., Inc.
Inspection date
July 11, 2025
Product type
drugs
Office
Office of Inspections and Investigations
Person
  • Crystal Monroy
View Company Profile

ID · 3739c52b-ab22-404e-8b64-7efa25723f2c

Other documents for Hisamitsu Pharmaceutical Co., Inc.
  • 483 - 2019-10-11October 11, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hisamitsu Pharmaceutical Co., Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.